Fidelis Capital Partners LLC Boosts Stake in Humana Inc. (NYSE:HUM)

Fidelis Capital Partners LLC boosted its stake in Humana Inc. (NYSE:HUM) by 16.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,002 shares of the insurance provider’s stock after buying an additional 145 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Humana were worth $459,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Rakuten Securities Inc. purchased a new position in shares of Humana during the 4th quarter worth $25,000. Gradient Investments LLC lifted its stake in shares of Humana by 200.0% during the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 40 shares during the period. Sunbelt Securities Inc. purchased a new position in shares of Humana during the 1st quarter worth $28,000. Nvwm LLC lifted its stake in shares of Humana by 41.0% during the 3rd quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock worth $42,000 after purchasing an additional 25 shares during the period. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in shares of Humana during the 4th quarter worth $55,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM stock opened at $328.33 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59. Humana Inc. has a one year low of $299.23 and a one year high of $541.21. The company’s 50-day simple moving average is $330.40 and its 200-day simple moving average is $400.99. The stock has a market capitalization of $39.61 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 1.90 and a beta of 0.45.

Humana (NYSE:HUM) last issued its quarterly earnings results on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.76 by ($0.87). Humana had a return on equity of 19.44% and a net margin of 2.34%. The company had revenue of $26.46 billion for the quarter, compared to the consensus estimate of $25.47 billion. During the same period in the previous year, the business posted $1.62 EPS. The business’s revenue for the quarter was up 17.9% on a year-over-year basis. Equities analysts anticipate that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, June 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.08%. Humana’s payout ratio is 17.86%.

Insider Transactions at Humana

In related news, Director Jorge S. Mesquita purchased 545 shares of Humana stock in a transaction dated Tuesday, February 20th. The shares were acquired at an average price of $367.09 per share, with a total value of $200,064.05. Following the completion of the transaction, the director now owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HUM. Bank of America restated a “neutral” rating and set a $342.00 price objective (down from $470.00) on shares of Humana in a report on Tuesday, April 2nd. UBS Group restated a “neutral” rating and set a $370.00 price objective (down from $530.00) on shares of Humana in a report on Friday, January 26th. Oppenheimer restated an “outperform” rating and set a $630.00 price objective on shares of Humana in a report on Wednesday, January 17th. StockNews.com downgraded Humana from a “strong-buy” rating to a “hold” rating in a report on Friday, January 26th. Finally, Barclays dropped their price objective on Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a report on Tuesday, April 2nd. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $465.42.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.